ymjЯкутский медицинский журналYakut Medical Journal1813-19052312-1017ЯНЦ КМП10.25789/YMJ.2021.75.25ymj-552Research ArticleНАУЧНЫЕ ОБЗОРЫ И ЛЕКЦИИSCIENTIFIC REVIEWS AND LECTURESТерапевтические подходы к восстановлению антиатерогенной функции липопротеинов высокой плотностиTherapeutic approaches to restoring the antiatherogenic function of high density lipoproteinshttps://orcid.org/0000-0003-1068-2431ПотеряеваО. Н.PoteryaevaO. N.

Потеряева Ольга Николаевна – д.м.н., в.н.с.

Poteryaeva Olga Nikolaevna - MD, research assistant

https://orcid.org/0000-0003-1752-9034УсынинИ. Ф.UsyninI. F.

Усынин Иван Фёдорович – д.б.н., зав. лаб.

Usynin Ivan Fedorovich - Doctor of Biological Sciences, head of the lab

НИИ биохимии ФИЦ фундаментальной и трансляционной медициныРоссияInstitute of Biochemistry, Federal Research Center of Fundamental and Translation MedicineRussian Federation2021270420250398103Copyright © Потеряева О.Н., Усынин И.Ф., 20252025Потеряева О.Н., Усынин И.Ф.Poteryaeva O.N., Usynin I.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ymj.elpub.ru/jour/article/view/552

Антиатерогенная функция липопротеинов высокой плотности (ЛПВП) связана с их участием в обратном транспорте избытка холестерина из периферических тканей в печень. Исследованиями последних лет показано, что антиатерогенная функция ЛПВП при различных патологических состояниях может изменяться, что приводит к появлению дисфункциональных ЛПВП, неспособных выполнять в организме защитные функции. Настоящий обзор посвящён анализу современных подходов, направленных как на повышение уровня ЛПВП в плазме крови, так и на сохранение и восстановление их функциональных свойств.

A low level of high density lipoproteins (HDLs) in blood plasma is considered to be an important risk factor for the development of atherosclerosis. The antiatherogenic function of HDLs is associated with their participation in the reverse transport of excess cholesterol from peripheral tissues to the liver. In addition, they have antioxidant, anti-inflammatory, antithrombotic and anti-infectious properties, which also contribute to their atheroprotective effect. Recent studies have shown that the structure and composition of HDLs can change under various pathological conditions, thus leading to the appearance of dysfunctional HDLs, which cannot perform protective functions in the body. This review is devoted to the analysis of modern approaches aimed both at increasing the level of HDLs in blood plasma and at maintaining and restoring their native functional properties.

атеросклерозлипопротеины высокой плотностиантиатерогенная функцияatherosclerosishigh density lipoproteinsantiatherogenic functionReferences2019 Рекомендации ESC/EAS по лечению дислипидемий: модификация липидов для снижения сердечно-сосудистого риска. Российский кардиологический журнал. 2020; 25(5): 3826. DOI: 10.15829/1560-4071-2020-38262019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk. Russian J. Cardiology. 2020; 25(5):3826. DOI: 10.15829/1560-4071-2020-3826Adams V, Besler C, Fischer T, Riwanto M, et al. Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties. Circ Res. 2013; 113(12): 1345–55. DOI: 10.1161/CIRCRESAHA.113.301684Adams V, Besler C, Fischer T, Riwanto M, et al. Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties. Circ Res. 2013; 113(12): 1345–55. DOI: 10.1161/CIRCRESAHA.113.301684Aminian A, Zajichek A, Arterburn DE et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA. 2019; 322: 1271–82. DOI: 10.1001/jama.2019.14231Aminian A, Zajichek A, Arterburn DE et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA. 2019; 322: 1271–82. DOI: 10.1001/jama.2019.14231Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. JACC. 2010; 55: 2580-2589. DOI: 10.1016/j.jacc.2010.02.035Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. JACC. 2010; 55: 2580-2589. DOI: 10.1016/j.jacc.2010.02.035Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. NEJM. 2007; 357(21): 2109-2122. DOI: 10.1056/NEJMoa0706628Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. NEJM. 2007; 357(21): 2109-2122. DOI: 10.1056/NEJMoa0706628Barter PJ, Rye KA. Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence? Clin Ther. 2015; 37: 2716-2731. DOI: 10.1016/j.clinthera.2015.07.021Barter PJ, Rye KA. Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence? Clin Ther. 2015; 37: 2716-2731. DOI: 10.1016/j.clinthera.2015.07.021Bougarne N, Weyers B, Desmet SJ., Deckers J, Ray DW, Staels B, De Bosscher K. Molecular actions of PPARalpha in lipid metabolism and inflammation. Endocr Rev. 2018; 39(5): 760-802. DOI: 10.1210/er.2018-00064.PMID: 30020428Bougarne N, Weyers B, Desmet SJ., Deckers J, Ray DW, Staels B, De Bosscher K. Molecular actions of PPARalpha in lipid metabolism and inflammation. Endocr Rev. 2018; 39(5): 760-802. DOI: 10.1210/er.2018-00064.PMID: 30020428Brites F, Martin M, Guillas I, Kontush A. Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit. BBA Clinical. 2017; 8: 66–77. DOI:10.1016/j.bbacli.2017.07.002Brites F, Martin M, Guillas I, Kontush A. Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit. BBA Clinical. 2017; 8: 66–77. DOI:10.1016/j.bbacli.2017.07.002Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010; (2): 353-61. DOI: 10.1016/j.atherosclerosis.2009.12.023Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010; (2): 353-61. DOI: 10.1016/j.atherosclerosis.2009.12.023Butcher LR, Thomas A, Backx K, Roberts A, Webb R, Morris K. Low- intensity exercise exerts beneficial effects on plasma lipids via PPARgamma. Med Sci Sports Exerc. 2008; 40: 1263–1270. DOI: 10.1249/MSS.0b013e31816c091dButcher LR, Thomas A, Backx K, Roberts A, Webb R, Morris K. Low- intensity exercise exerts beneficial effects on plasma lipids via PPARgamma. Med Sci Sports Exerc. 2008; 40: 1263–1270. DOI: 10.1249/MSS.0b013e31816c091dCanner PL, Furberg CD, McGovern ME. Benefits of Niacin in Patients With Versus Without the Metabolic Syndrome and Healed Myocardial Infarction (from the Coronary Drug Project). AM J Cardiol. 2006. 97(4), 477–479. DOI: 10.1016/j.amjcard.2005.08.070Canner PL, Furberg CD, McGovern ME. Benefits of Niacin in Patients With Versus Without the Metabolic Syndrome and Healed Myocardial Infarction (from the Coronary Drug Project). AM J Cardiol. 2006. 97(4), 477–479. DOI: 10.1016/j.amjcard.2005.08.070Casella-Filho A, Chagas AC, Maranhão RC, et al. Effect of exercise training on plasma levels and functional properties of high-density lipoproteincholesterol in the metabolic syndrome. Am J Cardiol. 2011; 107(8): 1168–1172. DOI: 10.1016/j.amjcard.2010.12.014Casella-Filho A, Chagas AC, Maranhão RC, et al. Effect of exercise training on plasma levels and functional properties of high-density lipoproteincholesterol in the metabolic syndrome. Am J Cardiol. 2011; 107(8): 1168–1172. DOI: 10.1016/j.amjcard.2010.12.014Chen W, Wu Y, Lu Q, Wang S, Xing D. Endogenous ApoA-I expression in macrophages: a potential target for protection against atherosclerosis. Clin Chim Acta. 2020; 505: 55-59. DOI: 10.1016/j.cca.2020.02.025Chen W, Wu Y, Lu Q, Wang S, Xing D. Endogenous ApoA-I expression in macrophages: a potential target for protection against atherosclerosis. Clin Chim Acta. 2020; 505: 55-59. DOI: 10.1016/j.cca.2020.02.025DeGoma EM, Rader DJ. Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol. 2011; 8(5): 266-277. DOI: 10.1038/nrcardio.2010.200DeGoma EM, Rader DJ. Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol. 2011; 8(5): 266-277. DOI: 10.1038/nrcardio.2010.200Dunbar RL, Movva R, Bloedon LT, et al. Oral apolipoprotein A-I mimetic D-4F lowers HDL-inflammatory index in high-risk patients: a first-in-human multiple-dose, randomized controlled trial. Clin Transl Sci. 2017; 10: 455–469. DOI: 10.1111/cts.12487Dunbar RL, Movva R, Bloedon LT, et al. Oral apolipoprotein A-I mimetic D-4F lowers HDL-inflammatory index in high-risk patients: a first-in-human multiple-dose, randomized controlled trial. Clin Transl Sci. 2017; 10: 455–469. DOI: 10.1111/cts.12487Gebhard C, Rheaume E, Berry C, et al. Beneficial effects of reconstituted high-density lipoprotein (rHDL) on circulating CD34+ cells in patients after an acute coronary syndrome. PLOS ONE. 2017; 12(1): e0168448. DOI: 10.1371/journal.pone.0168448Gebhard C, Rheaume E, Berry C, et al. Beneficial effects of reconstituted high-density lipoprotein (rHDL) on circulating CD34+ cells in patients after an acute coronary syndrome. PLOS ONE. 2017; 12(1): e0168448. DOI: 10.1371/journal.pone.0168448Ghanbari-Niaki A, Ghanbari-Abarghooi S, Rahbarizadeh F, Zare-Kookandeh N, Gholizadeh M, Roudbari F, Zare-Kookandeh A. Heart ABCA1 and PPAR-α genes expression responses in male rats: effects of high intensity treadmill running training and aqueous extraction of black crataegus-pentaegyna. Res Cardiovasc Med. 2013; 2(4): 153–159. DOI: 10.5812/cardiovascmed.13892Ghanbari-Niaki A, Ghanbari-Abarghooi S, Rahbarizadeh F, Zare-Kookandeh N, Gholizadeh M, Roudbari F, Zare-Kookandeh A. Heart ABCA1 and PPAR-α genes expression responses in male rats: effects of high intensity treadmill running training and aqueous extraction of black crataegus-pentaegyna. Res Cardiovasc Med. 2013; 2(4): 153–159. DOI: 10.5812/cardiovascmed.13892Gille A, D’Andrea D, Tortorici MA, Hartel G, Wright SD. CSL112 (apolipoprotein A-I [human]) enhances cholesterol efflux similarly in healthy individuals and stable atherosclerotic disease patients highlights. Arterioscler Thromb Vasc Biol. 2018; 38(4): 953–963. DOI:10.1161/atvbaha.118.310538Gille A, D’Andrea D, Tortorici MA, Hartel G, Wright SD. CSL112 (apolipoprotein A-I [human]) enhances cholesterol efflux similarly in healthy individuals and stable atherosclerotic disease patients highlights. Arterioscler Thromb Vasc Biol. 2018; 38(4): 953–963. DOI:10.1161/atvbaha.118.310538Gordon SM, Amar MJ, Jeiran K, Stagliano M, Staller E, Playford MP, Mehta NN, Vaisar T, Remaley AT. Effect of niacin monotherapy on high density lipoprotein composition and function. Lipids Health Dis. 2020; 19(1):190. DOI: 10.1186/s12944-020-01350-3Gordon SM, Amar MJ, Jeiran K, Stagliano M, Staller E, Playford MP, Mehta NN, Vaisar T, Remaley AT. Effect of niacin monotherapy on high density lipoprotein composition and function. Lipids Health Dis. 2020; 19(1):190. DOI: 10.1186/s12944-020-01350-3Hernaez A, Castaner O, Elosua R, Pinto X, Estruch R, Salas-Salvado J, Corella D, Arós F, Serra-Majem L, Fiol M, Ortega-Calvo M, Ros E, Martínez-González MA, de la Torre R, López-Sabater MC, Fitó M. Mediterranean diet improves high-density lipoprotein function in high-cardiovascular-risk individuals: a randomized controlled trial. Circulation. 2017; 135(7): 633-643. DOI: 10.1161/CIRCULATIONAHA.116.023712Hernaez A, Castaner O, Elosua R, Pinto X, Estruch R, Salas-Salvado J, Corella D, Arós F, Serra-Majem L, Fiol M, Ortega-Calvo M, Ros E, Martínez-González MA, de la Torre R, López-Sabater MC, Fitó M. Mediterranean diet improves high-density lipoprotein function in high-cardiovascular-risk individuals: a randomized controlled trial. Circulation. 2017; 135(7): 633-643. DOI: 10.1161/CIRCULATIONAHA.116.023712Hoang A, Tefft C, Duffy SJ, Formosa M, Henstridge DC, Kingwell BA. et al. ABCA1 expression in humans is associated with physical activity and alcohol consumption. Atherosclerosis. 2008; 197: 197–203. DOI: 10.1016/j.atherosclerosis.2007.03.017Hoang A, Tefft C, Duffy SJ, Formosa M, Henstridge DC, Kingwell BA. et al. ABCA1 expression in humans is associated with physical activity and alcohol consumption. Atherosclerosis. 2008; 197: 197–203. DOI: 10.1016/j.atherosclerosis.2007.03.017Hou L, Tang S, Wu BJ, Ong KL, Westerterp M, Barter PJ, Cochran BJ, Tabet F, Rye KA. Apolipoprotein A-I improves pancreatic β-cell function independent of the ATP-binding cassette transporters ABCA1 and ABCG1. FASEB J. 2019; 33(7): 8479-8489. DOI: 10.1096/fj.201802512RR.Hou L, Tang S, Wu BJ, Ong KL, Westerterp M, Barter PJ, Cochran BJ, Tabet F, Rye KA. Apolipoprotein A-I improves pancreatic β-cell function independent of the ATP-binding cassette transporters ABCA1 and ABCG1. FASEB J. 2019; 33(7): 8479-8489. DOI: 10.1096/fj.201802512RR.Hovingh GK, Smits LP, Stefanutti C, et al. The effect of an apolipoprotein A-I-containing high-density lipoproteinmimetic particle (CER001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: the modifying orphan disease evaluation (MODE) study. Am Heart J. 2015; 169: 736-742.e1. DOI: 10.1016/j.ahj.2015.01.008Hovingh GK, Smits LP, Stefanutti C, et al. The effect of an apolipoprotein A-I-containing high-density lipoproteinmimetic particle (CER001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: the modifying orphan disease evaluation (MODE) study. Am Heart J. 2015; 169: 736-742.e1. DOI: 10.1016/j.ahj.2015.01.008Jomard A, Osto E. High density lipoprotein: metabolism, function, and therapeutic potential. Front Cardiovasc Med. 2020; 7(39): 1-12. DOI: 10.3389/fcvm.2020.00039Jomard A, Osto E. High density lipoprotein: metabolism, function, and therapeutic potential. Front Cardiovasc Med. 2020; 7(39): 1-12. DOI: 10.3389/fcvm.2020.00039Kataoka Y, Andrews J, Duong M, et al. Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden. Cardiovasc Diagn Ther. 2017; 7: 252-63. DOI: 10.21037/cdt.2017.02.01Kataoka Y, Andrews J, Duong M, et al. Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden. Cardiovasc Diagn Ther. 2017; 7: 252-63. DOI: 10.21037/cdt.2017.02.01Kootte RS, Smits LP, van der Valk FM, et al. Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J Lipid Res. 2015; 56: 703-712. DOI: 10.1194/jlr.M055665Kootte RS, Smits LP, van der Valk FM, et al. Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J Lipid Res. 2015; 56: 703-712. DOI: 10.1194/jlr.M055665Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. NEJM. 2017; 376(20): 1933–1942. DOI: 10.1056/NEJMoa1609581Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. NEJM. 2017; 376(20): 1933–1942. DOI: 10.1056/NEJMoa1609581Liu D, Ding Z, Wu M, Xu W, et al. The apolipoprotein A-I mimetic peptide, D-4F, alleviates ox-LDL-induced oxidative stress and promotes endothelial repair through the eNOS/HO-1 path way. JMCC. 2017; 105: 77-88. DOI:10.1016/j.yjmcc.2017.01.017Liu D, Ding Z, Wu M, Xu W, et al. The apolipoprotein A-I mimetic peptide, D-4F, alleviates ox-LDL-induced oxidative stress and promotes endothelial repair through the eNOS/HO-1 path way. JMCC. 2017; 105: 77-88. DOI:10.1016/j.yjmcc.2017.01.017Marques LR, Diniz TA, Antunes BM, Rossi FE, Caperuto EC, Lira FS, Gonçalves DC. Reverse cholesterol transport: molecular mechanisms and the non-medical approach to enhance HDL cholesterol. Front Physiol. 2018; 9: 526. DOI: 10.3389/fphys.2018.00526Marques LR, Diniz TA, Antunes BM, Rossi FE, Caperuto EC, Lira FS, Gonçalves DC. Reverse cholesterol transport: molecular mechanisms and the non-medical approach to enhance HDL cholesterol. Front Physiol. 2018; 9: 526. DOI: 10.3389/fphys.2018.00526Masson W, Lobo M, Siniawski D, Huerin M, Molinero G, Valero R, Nogueiraet JP. Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk. Diabetes Metab. 2018; 44: 508-513. DOI: 10.1016/j.diabet.2018.02.005Masson W, Lobo M, Siniawski D, Huerin M, Molinero G, Valero R, Nogueiraet JP. Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk. Diabetes Metab. 2018; 44: 508-513. DOI: 10.1016/j.diabet.2018.02.005Nicholls SJ, Andrews J, Kastelein JJP, et al. Effect of serial infusions of CER-001, a pre-β high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression acute coronary syndrome trial: a randomized clinical trial. JAMA Cardiol. 2018; 3(9): 815-822. DOI: 10.1001/jamacardio.2018.2121Nicholls SJ, Andrews J, Kastelein JJP, et al. Effect of serial infusions of CER-001, a pre-β high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression acute coronary syndrome trial: a randomized clinical trial. JAMA Cardiol. 2018; 3(9): 815-822. DOI: 10.1001/jamacardio.2018.2121Nicholls SJ, Puri R, Wolski K, et al. Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE trial. Am J Cardiovasc Drugs. 2016; 16(1), 55-65. DOI: 10.1007/s40256-015-0146-zNicholls SJ, Puri R, Wolski K, et al. Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE trial. Am J Cardiovasc Drugs. 2016; 16(1), 55-65. DOI: 10.1007/s40256-015-0146-zNgo Sock SE, Chapados NA, Lavoie JM. LDL receptor and Pcsk9 transcripts are decreased in liver of ovariectomized rats: effects of exercise training. Horm Metab Res. 2014; 46: 550–555. DOI: 10.1055/s-0034-1370910Ngo Sock SE, Chapados NA, Lavoie JM. LDL receptor and Pcsk9 transcripts are decreased in liver of ovariectomized rats: effects of exercise training. Horm Metab Res. 2014; 46: 550–555. DOI: 10.1055/s-0034-1370910Nikolic D, Rizzo M, Mikhailidis DP, Wong NC, Banach M. An evaluation of RVX-208 for the treatment of atherosclerosis. Expert Opin Investig Drugs. 2015; 24(10): 1389–1398. DOI:10.1517/13543784.2015.1083010Nikolic D, Rizzo M, Mikhailidis DP, Wong NC, Banach M. An evaluation of RVX-208 for the treatment of atherosclerosis. Expert Opin Investig Drugs. 2015; 24(10): 1389–1398. DOI:10.1517/13543784.2015.1083010Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003; 290(17): 2292–2300. DOI: 10.1001/jama.290.17.2292Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003; 290(17): 2292–2300. DOI: 10.1001/jama.290.17.2292Osto E, Doytcheva P, Corteville C, Bueter M, Dorig C, Stivala S, et al. Rapid and body weight-independent improvement of endothelial and high-density lipoprotein function after Roux-en-Y gastric bypass: role of glucagon-like peptide. Circulation. 2015; 131(10): 871-881. DOI: 10.1161/CIRCULATIONAHA.114.011791Osto E, Doytcheva P, Corteville C, Bueter M, Dorig C, Stivala S, et al. Rapid and body weight-independent improvement of endothelial and high-density lipoprotein function after Roux-en-Y gastric bypass: role of glucagon-like peptide. Circulation. 2015; 131(10): 871-881. DOI: 10.1161/CIRCULATIONAHA.114.011791Parolini C, Adorni MP, Busnelli M, Manzini S, Cipollari E, Favari E, Lorenzon P, Ganzetti GS, Fingerle J, Bernini F, Chiesa G. Can infusions of large synthetic HDL containing trimeric apoA-I stabilize atherosclerotic plaques in hypercholesterolemic rabbits. J Cardiol. 2019; 35(10): 1400-1408. DOI: 10.1016/j.cjca.2019.05.033Parolini C, Adorni MP, Busnelli M, Manzini S, Cipollari E, Favari E, Lorenzon P, Ganzetti GS, Fingerle J, Bernini F, Chiesa G. Can infusions of large synthetic HDL containing trimeric apoA-I stabilize atherosclerotic plaques in hypercholesterolemic rabbits. J Cardiol. 2019; 35(10): 1400-1408. DOI: 10.1016/j.cjca.2019.05.033Poteryaeva ON, Usynin IF. Antidiabetic role of high density lipoproteins. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry. 2019; 13(2): 113-121. DOI: 10.1134/S1990750819020070Poteryaeva ON, Usynin IF. Antidiabetic role of high density lipoproteins. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry. 2019; 13(2): 113-121. DOI: 10.1134/S1990750819020070Riwanto M, Landmesser U. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J. Lipid. Res. 2013; 54, 3227–3243. DOI: 10.1194/jlr.R037762Riwanto M, Landmesser U. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J. Lipid. Res. 2013; 54, 3227–3243. DOI: 10.1194/jlr.R037762Rosenson RS, Brewer HB, Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016; 13(1): 48–60. DOI: 10.1038/nrcardio.2015.124Rosenson RS, Brewer HB, Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016; 13(1): 48–60. DOI: 10.1038/nrcardio.2015.124Rye K-A, Barter PJ. Cardioprotective functions of HDLs. J Lipid Res. 2013; 55(2): 168-179. DOI: 10.1194/jlr.R039297Rye K-A, Barter PJ. Cardioprotective functions of HDLs. J Lipid Res. 2013; 55(2): 168-179. DOI: 10.1194/jlr.R039297Schmiedtova M, Heczkova M, Kovar J, Kralova LI, Poledne R. Reverse transport of cholesterol is the reason for resistance to development of atherosclerosis in Prague hereditary hypercholesterolemic (PHHC) rat. Physiol Res. 2014; 63(5): 591-6.Schmiedtova M, Heczkova M, Kovar J, Kralova LI, Poledne R. Reverse transport of cholesterol is the reason for resistance to development of atherosclerosis in Prague hereditary hypercholesterolemic (PHHC) rat. Physiol Res. 2014; 63(5): 591-6.Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. NEJM. 2012; 367: 2089-2099. DOI: 10.1056/NEJMoa1206797Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. NEJM. 2012; 367: 2089-2099. DOI: 10.1056/NEJMoa1206797Shaw JA, Bobik A, Murphy A, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res. 2008; 103(10): 1084-1091. DOI: 10.1161/CIRCRESAHA.108.182063Shaw JA, Bobik A, Murphy A, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res. 2008; 103(10): 1084-1091. DOI: 10.1161/CIRCRESAHA.108.182063Soran H, Schofield J D, Durrington P. N. Antioxidant properties of HDL. Front Pharmacol. 2015; 6: 222. DOI: 10.3389/fphar.2015.00222Soran H, Schofield J D, Durrington P. N. Antioxidant properties of HDL. Front Pharmacol. 2015; 6: 222. DOI: 10.3389/fphar.2015.00222Tabet F, Cuesta Torres LF, Ong KL, Shrestha S, Choteau SA, Barter PJ, Clifton P, Rye R-A. High-density lipoprotein-associated miR-223 is altered after diet-induced weight loss in overweight and obese males. PLoS ONE. 2016; 11(3): e0151061. DOI: 10.1371/journal.pone.0151061Tabet F, Cuesta Torres LF, Ong KL, Shrestha S, Choteau SA, Barter PJ, Clifton P, Rye R-A. High-density lipoprotein-associated miR-223 is altered after diet-induced weight loss in overweight and obese males. PLoS ONE. 2016; 11(3): e0151061. DOI: 10.1371/journal.pone.0151061Takata K, Di Bartolo BA, Nicholls SJ. High-density lipoprotein infusions. Cardiol Clin. 2018; 36(2): 311-315. DOI:10.1016/j.ccl.2017.12.012Takata K, Di Bartolo BA, Nicholls SJ. High-density lipoprotein infusions. Cardiol Clin. 2018; 36(2): 311-315. DOI:10.1016/j.ccl.2017.12.012Tall AR., Rader DJ. Trials and tribulations of CETP inhibitors. Circ Res. 2018; 122(1): 106–12. DOI: 10.1161/CIRCRESAHA.117.311978Tall AR., Rader DJ. Trials and tribulations of CETP inhibitors. Circ Res. 2018; 122(1): 106–12. DOI: 10.1161/CIRCRESAHA.117.311978Tardif JC, Ballantyne CM, Barter P, et al. Effects of the high density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J., 2014; 35(46), 3277-3286. DOI: 10.1093/eurheartj/ehu171Tardif JC, Ballantyne CM, Barter P, et al. Effects of the high density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J., 2014; 35(46), 3277-3286. DOI: 10.1093/eurheartj/ehu171Tardy C, Goffinet M, Boubekeur N, et al. HDL and CER001 inverse-dose dependent inhibition of atherosclerotic plaque formation in apoE-/-mice: evidence of ABCA1 down-regulation. PLOS ONE. 2015; 10:e0137584. DOI: 10.1371/journal.pone.0137584Tardy C, Goffinet M, Boubekeur N, et al. HDL and CER001 inverse-dose dependent inhibition of atherosclerotic plaque formation in apoE-/-mice: evidence of ABCA1 down-regulation. PLOS ONE. 2015; 10:e0137584. DOI: 10.1371/journal.pone.0137584The HPS3/TIMI55–REVEAL Collaborative Group. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. NEJM. 2017; 377(13), 1217-1227. DOI: 10.1056/NEJMoa1706444The HPS3/TIMI55–REVEAL Collaborative Group. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. NEJM. 2017; 377(13), 1217-1227. DOI: 10.1056/NEJMoa1706444The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014; 371(3): 203-212. DOI: 10.1056/NEJMoa1300955The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014; 371(3): 203-212. DOI: 10.1056/NEJMoa1300955Vaisberg M, Bachi AL, Latrilha C, Dioguardi GS, Bydlowski SP, Maranhão RC. Lipid transfer to HDL is higher in marathon runners than in sedentary subjects, but is acutely inhibited during the run. Lipids. 2012; 47: 679–686. DOI: 10.1007/s11745-012-3685-yVaisberg M, Bachi AL, Latrilha C, Dioguardi GS, Bydlowski SP, Maranhão RC. Lipid transfer to HDL is higher in marathon runners than in sedentary subjects, but is acutely inhibited during the run. Lipids. 2012; 47: 679–686. DOI: 10.1007/s11745-012-3685-yXu W, Qian M, Huang C, et al. Comparison of mechanisms of endothelial cell protections between high-density lipoprotein and apolipoprotein A-I mimetic peptide. Front Pharmacol. 2019; 10: 817. DOI: 10.3389/fphar.2019.00817Xu W, Qian M, Huang C, et al. Comparison of mechanisms of endothelial cell protections between high-density lipoprotein and apolipoprotein A-I mimetic peptide. Front Pharmacol. 2019; 10: 817. DOI: 10.3389/fphar.2019.00817Zhang S, Liu Y, Li Q. et al. Exercise improved rat metabolism by raising PPAR-α. Int J Sports Med. 2011; 32: 568–573. DOI: 10.1055/s0031-1271755Zhang S, Liu Y, Li Q. et al. Exercise improved rat metabolism by raising PPAR-α. Int J Sports Med. 2011; 32: 568–573. DOI: 10.1055/s0031-1271755Zhao Q, Li J, Yang J, Li R. Association of total cholesterol and HDL-C levels and outcome in coronary heart disease patients with heart failure. Medicine (Baltimore). 2017; 96(9):e6094. DOI: 10.1097/MD.0000000000006094Zhao Q, Li J, Yang J, Li R. Association of total cholesterol and HDL-C levels and outcome in coronary heart disease patients with heart failure. Medicine (Baltimore). 2017; 96(9):e6094. DOI: 10.1097/MD.0000000000006094

The authors declare that there are no conflicts of interest present.